Dopamine D3 receptor agonists for protection and repair in Parkinson's disease

Current Opinion in Pharmacology

Volumn 7, Issue 1, 2007, Pages 100-105

  Joyce, Jeffrey N ^a   Millan, Mark J ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; NEUROTROPHIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRAMIPEXOLE; PROTEIN KINASE B; ROPINIROLE; S 32504; UNCLASSIFIED DRUG;

BINDING AFFINITY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVATION; GENE THERAPY; GENE VECTOR; HUMAN; MOTOR DYSFUNCTION; NEURAL STEM CELL; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA;

ANIMALS; DOPAMINE AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D3;

EID: 33846900714     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.11.004     Document Type: Review

References (46)

1. Schapira A.H. Etiology of Parkinson's disease. Neurology 66 (2006) S10-S23
2. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 252 Suppl 4 (2005) IV37-IV42
3. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90 (2001) 231-259
4. Clarke C.E., and Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 360 (2002) 1767-1769
5. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65 (2001) 135-172
6. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318 (2004) 215-224
7. Gerlach M., and Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103 (1996) 987-1041
8. Jenner P., and Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 66 (2006) S24-S36
9. Sayles M., Jain M., and Barker R.A. The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl Immunol 12 (2004) 321-342
10. Yurek D.M., and Fletcher-Turner A. Comparison of embryonic stem cell-derived dopamine neuron grafts and fetal ventral mesencephalic tissue grafts: morphology and function. Cell Transplant 13 (2004) 295-306
11. Pearce R.K., Costa S., Jenner P., and Marsden C.D. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J Neural Transm 106 (1999) 663-683
12. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., and Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 (2002) 2191-2201
13. Björklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., and Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886 (2000) 82-98
14. Sun M., Kong L., Wang X., Lu X.G., Gao Q., and Geller A.I. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 1052 (2005) 119-129
15. Sun M., Kong L., Wang X., Holmes C., Gao Q., Zhang G.R., Pfeilschifter J., Goldstein D.S., and Geller A.I. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum Gene Ther 15 (2004) 1177-1196
16. Joyce J.N., and Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10 (2005) 917-925
17. Neve K.A., Seamans J.K., and Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24 (2004) 165-205
18. Bozzi Y., and Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci 29 (2006) 167-174
19. Millan M.J., Brocco M., Papp M., Serres F., La Rochelle C.D., Sharp T., Peglion J.L., and Dekeyne A. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J Pharmacol Exp Ther 309 (2004) 936-950
20. Millan M.J., Di Cara B., Hill M., Jackson M., Joyce J.N., Brotchie J., McGuire S., Crossman A., Smith L., Jenner P., et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther 309 (2004) 921-935
21. Millan M.J., Cussac D., Gobert A., Lejeune F., Rivet J.M., La Cour C.M., Newman-Tancredi A., and Peglion J.L. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. J Pharmacol Exp Ther 309 (2004) 903-920
22. 2 receptor agonist and antiparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+)and in vivo against 1-methyl- 4-phenyl-1,2,2,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp Neurol 184 (2003) 393-407
23. Joyce J.N., Woolsey C., Ryoo H., Borwege S., and Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2 (2004) 22
24. Iravani M.M., Haddon C.O., Cooper J.M., Jenner P., and Schapira A.H. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96 (2006) 1315-1321
25. Vu T.Q., Ling Z.D., Ma S.Y., Robie H.C., Tong C.W., Chen E.Y., Lipton J.W., and Carvey P.M. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 107 (2000) 159-176
26. Ramirez A.D., Wong S.K., and Menniti F.S. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol 475 (2003) 29-35
27. Anderson D.W., Neavin T., Smith J.A., and Schneider J.S. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 905 (2001) 44-53
28. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22 (2005) 2422-2430. Using a mesencephalic primary cell culture, D3 receptor agonist-conditioned media enhanced the growth of DA neurons in freshly harvested recipient cultures, implicating a D3 receptor-mediated trophic activity in the neuroprotective effect. This effect was blocked with BDNF- and GDNF-neutralizing antibodies, confirming the mediation of protection by neurotrophins.
29. Presgraves S.P., Ahmed T., Borwege S., and Joyce J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res 5 (2004) 579-598
30. Presgraves S.P., Borwege S., Millan M.J., and Joyce J.N. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol 190 (2004) 157-170
31. Porritt M.J., Batchelor P.E., and Howells D.W. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol 192 (2005) 226-234
32. Hetman M., Kanning K., Cavanaugh J.E., and Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem 274 (1999) 22569-22580
33. Van Kampen J.M., Hagg T., and Robertson H.A. Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur J Neurosci 19 (2004) 2377-2387
34. ••].
35. Van Kampen J.M., and Eckman C.B. Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26 (2006) 7272-7280. Demonstrated that chronic intraventricular administration of 7-OH-DPAT triggers a profound induction of cell proliferation in the rat SN and promotes the adoption of a neuronal phenotype that exhibits dopaminergic characteristics. These cells make a connection with the striatum in a partially lesioned DA system, as determined by FlouroGold labeling of the BrdU-positive cells in the SN following injection in the striatum.
36. Ferretti P. Neural stem cell plasticity: recruitment of endogenous populations for regeneration. Curr Neurovasc Res 1 (2004) 215-229
37. De Marchis S., Fasolo A., and Puche A.C. Subventricular zone-derived neuronal progenitors migrate into the subcortical forebrain of postnatal mice. J Comp Neurol 476 (2004) 290-300
38. Gould E., and Gross C.G. Neurogenesis in adult mammals: some progress and problems. J Neurosci 22 (2002) 619-623
39. Coronas V., Bantubungi K., Fombonne J., Krantic S., Schiffmann S.N., and Roger M. Dopamine D3 receptor stimulation promotes the proliferation of cells derived from the post-natal subventricular zone. J Neurochem 91 (2004) 1292-1301
40. 3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20 (2000) 8677-8684
41. Lie D.C., Dziewczapolski G., Willhoite A.R., Kaspar B.K., Shults C.W., and Gage F.H. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 22 (2002) 6639-6649
42. Zhao M., Momma S., Delfani K., Carlen M., Cassidy R.M., Johansson C.B., Brismar H., Shupliakov O., Frisen J., and Janson A.M. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 100 (2003) 7925-7930
43. Arias-Carrion O., Hernandez-Lopez S., Ibanez-Sandoval O., Bargas J., Hernandez-Cruz A., and Drucker-Colin R. Neuronal precursors within the adult rat subventricular zone differentiate into dopaminergic neurons after substantia nigra lesion and chromaffin cell transplant. J Neurosci Res 84 (2006) 1425-1437
44. Freundlieb N., Francois C., Tande D., Oertel W.H., Hirsch E.C., and Hoglinger G.U. Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci 26 (2006) 2321-2325
45. Shan X., Chi L., Bishop M., Luo C., Lien L., Zhang Z., and Liu R. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phyenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem cells 24 (2006) 1280-1287
46. Hermann A., Maisel M., Wegner F., Liebau S., Kim D.W., Gerlach M., Schwarz J., Kim K.S., and Storch A. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem cells 24 (2006) 949-964